{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T23:07:55Z","timestamp":1791241675110,"version":"4.1.0"},"update-to":[{"DOI":"10.1002\/14651858.cd007929.pub2","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2015,5,20]],"date-time":"2015-05-20T00:00:00Z","timestamp":1432080000000}}],"reference-count":80,"publisher":"Wiley","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd007929.pub3","type":"journal-article","created":{"date-parts":[[2015,5,20]],"date-time":"2015-05-20T10:32:23Z","timestamp":1432117943000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer"],"prefix":"10.1002","author":[{"given":"Alison J","family":"Wiggans","sequence":"first","affiliation":[{"name":"Musgrove Park Hospital; Department of Obstetrics and Gynaecology; Taunton and Somerset NHS Foundation Trust Taunton Somerset UK TA1 5DA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gemma KS","family":"Cass","sequence":"additional","affiliation":[{"name":"Musgrove Park Hospital; Department of Obstetrics and Gynaecology; Taunton and Somerset NHS Foundation Trust Taunton Somerset UK TA1 5DA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Bryant","sequence":"additional","affiliation":[{"name":"Newcastle University; Institute of Health & Society; Medical School New Build Richardson Road Newcastle upon Tyne UK NE2 4AX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theresa A","family":"Lawrie","sequence":"additional","affiliation":[{"name":"Royal United Hospital; Cochrane Gynaecological, Neuro-oncology and Orphan Cancer Group; Education Centre Bath UK BA1 3NG"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo","family":"Morrison","sequence":"additional","affiliation":[{"name":"Musgrove Park Hospital; Department of Gynaecological Oncology; Taunton and Somerset NHS Foundation Trust Taunton Somerset UK TA1 5DA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,5,20]]},"reference":[{"key":"10.1002\/14651858.CD007929.pub3-BIB0002|cit1","unstructured":"Kaye SB ICEBERG3 http:\/\/clinicaltrials.gov\/show\/NCT00628251"},{"issue":"4","key":"10.1002\/14651858.CD007929.pub3-BIB0001|cit2","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1200\/JCO.2011.36.9215","article-title":"Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer","volume":"30","author":"Kaye","year":"2012","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD007929.pub3-BIB0003|cit3","doi-asserted-by":"publisher","first-page":"2562","DOI":"10.1158\/1078-0432.CCR-14-2565","article-title":"Randomized trial of oral cyclophosphamide and veliparib in high-grade serous ovarian, primary peritoneal, or fallopian tube cancers, or BRCA-mutant ovarian cancer","volume":"14","author":"Kummar","year":"2015","journal-title":"Clinical Cancer Research"},{"issue":"15 Suppl","key":"10.1002\/14651858.CD007929.pub3-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"5020","DOI":"10.1200\/jco.2012.30.15_suppl.5020","article-title":"Randomized trial of oral cyclophosphamide \u00a9 with or without veliparib (V), an oral poly (ADP-ribose) polymerase (PARP) inhibitor, in patients with recurrent BRCA-positive ovarian, or primary peritoneal or high-grade serous ovarian carcinoma. 2012 ASCO Annual Meeting","volume":"30","author":"Kummar","year":"2012","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD007929.pub3-BIB0009|cit5","unstructured":"Ledermann J Assessment of efficacy of AZD2281 in platinum sensitive relapsed serous ovarian cancer http:\/\/clinicaltrials.gov\/show\/NCT00753545"},{"key":"10.1002\/14651858.CD007929.pub3-BIB0005|cit6","doi-asserted-by":"crossref","unstructured":"Ledermann J Harter P Gourley C Friedlander M Vergote I Rustin G Scott C Meier W Shapira Frommer R Safra T Matei D Macpherson E Watkins C Carmichael J Matulonis U Phase 2 randomized placebo-controlled study of olaparib (AZD2281) in patients with platinum-sensitive relapsed serous ovarian cancer (PSR SOC) International journal of gynecological cancer 2011","DOI":"10.1200\/jco.2011.29.15_suppl.5003"},{"issue":"8","key":"10.1002\/14651858.CD007929.pub3-BIB0006|cit7","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/S1470-2045(14)70228-1","article-title":"Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: A preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial","volume":"15","author":"Ledermann","year":"2014","journal-title":"Lancet oncology"},{"issue":"15","key":"10.1002\/14651858.CD007929.pub3-BIB0007|cit8","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1056\/NEJMoa1105535","article-title":"Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer","volume":"366","author":"Ledermann","year":"2012","journal-title":"New England Journal of Medicine"},{"issue":"(10)","key":"10.1002\/14651858.CD007929.pub3-BIB0008|cit9","first-page":"594","article-title":"Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: A preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial","volume":"69","author":"Ledermann","year":"2015","journal-title":"Obstetrical & gynecological survey"},{"key":"10.1002\/14651858.CD007929.pub3-BIB0010|cit10","doi-asserted-by":"crossref","unstructured":"Ledermann JA Harter P Gourley C Friedlander M Vergote IB Rustin GJS Scott C Meier W Shapira-Frommer R Safra T Matei D Macpherson E Watkins C Carmichael J Matulonis U Phase II randomized placebo-controlled study of olaparib (AZD2281) in patients with platinum-sensitive relapsed serous ovarian cancer (PSR SOC) Journal of clinical oncology 2011","DOI":"10.1200\/jco.2011.29.15_suppl.5003"},{"key":"10.1002\/14651858.CD007929.pub3-BIB0011|cit11","doi-asserted-by":"crossref","unstructured":"Matulonis UA Harter P Gourley C Friedlander M Vergote IB Rustin GJS Fielding A Spencer S Ho TW Ledermann JA Analysis of intermediate clinical endpoints from a Phase II trial of olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer (PSR SOC) Gynecologic oncology 2014;Conference: 45th Annual Meeting on Women's Cancer of the Society of Gynecologic Oncology, SGO 2014 Tampa, FL United States. Conference Start: 20140322 Conference End: 20140325. Conference Publication:(var.pagings):54-55 2014","DOI":"10.1016\/j.ygyno.2014.03.152"},{"key":"10.1002\/14651858.CD007929.pub3-BIB0012|cit12","doi-asserted-by":"crossref","unstructured":"Oza A Cibula D Oaknin Benzaquen A Poole C Mathijssen RHJ Sonke GS Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase II trial Lancet Oncology 2015; 87 97","DOI":"10.1016\/S1470-2045(14)71135-0"},{"issue":"15 Suppl","key":"10.1002\/14651858.CD007929.pub3-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"5001","DOI":"10.1200\/jco.2012.30.15_suppl.5001","article-title":"Olaparib plus paclitaxel plus carboplatin (P\/C) followed by olaparib maintenance treatment in patients (pts) with platinum-sensitive recurrent serous ovarian cancer (PSR SOC): A randomized, open-label phase II study","volume":"30","author":"Oza","year":"2012","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD007929.pub3-BIB0014|cit14","first-page":"S712","article-title":"Olaparib plus chemotherapy, followed by maintenance monotherapy, in women with platinum-sensitive recurrent serous ovarian cancer (PSR SOC): BRCA1\/2 mutation (BRCAm) and interim overall survival analyses","volume":"49 Suppl 2","author":"Oza","year":"2013","journal-title":"European Journal of Cancer"},{"issue":"22","key":"10.1002\/14651858.CD007929.pub3-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"3785","DOI":"10.1200\/JCO.2008.16.0812","article-title":"A synthetic lethal therapeutic approach: Poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair","volume":"26","author":"Ashworth","year":"2008","journal-title":"Journal of Clinical Oncology"},{"issue":"15S","key":"10.1002\/14651858.CD007929.pub3-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"5500","DOI":"10.1200\/jco.2009.27.15_suppl.5500","article-title":"Phase II trial of the oral PARP inhibitor olaparib (AZD2281) in BRCA-deficient advanced ovarian cancer","volume":"27","author":"Audeh","year":"2009","journal-title":"Journal of Clinical Oncology (Meeting Abstracts)"},{"issue":"9737","key":"10.1002\/14651858.CD007929.pub3-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0140-6736(10)60893-8","article-title":"Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial","volume":"376","author":"Audeh","year":"2010","journal-title":"Lancet"},{"issue":"5","key":"10.1002\/14651858.CD007929.pub3-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1158\/1078-0432.CCR-12-2243","article-title":"New strategies in the treatment of ovarian cancer: current clinical perspectives and future potential","volume":"19","author":"Banerjee","year":"2013","journal-title":"Clinical Cancer Research"},{"issue":"2","key":"10.1002\/14651858.CD007929.pub3-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s00404-013-2856-2","article-title":"Olaparib: a promising PARP inhibitor in ovarian cancer therapy","volume":"288","author":"Chen","year":"2013","journal-title":"Archives of Gynecology and Obstetrics"},{"key":"10.1002\/14651858.CD007929.pub3-BIB0020|cit20","doi-asserted-by":"crossref","unstructured":"Coleman RL Sill M Aghajanian C Gray HJ Tewari KS Rubin SC Rutherford TJ Chan JK Chen HX Swisher EM A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - A Gynecologic Oncology Group study Gynecologic oncology 2014 56 57","DOI":"10.1016\/j.ygyno.2014.03.156"},{"key":"10.1002\/14651858.CD007929.pub3-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1196\/annals.1414.020","article-title":"The potential of PARP inhibitors in genetic breast and ovarian cancers","volume":"1138","author":"Drew","year":"2008","journal-title":"Annals of the New York Academy of Science"},{"issue":"18 Suppl","key":"10.1002\/14651858.CD007929.pub3-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"3022","DOI":"10.1200\/jco.2006.24.18_suppl.3022","article-title":"Phase I pharmacokinetic (PK) and pharmacodynamic (PD) evaluation of a small molecule inhibitor of Poly ADP-Ribose Polymerase (PARP), KU-0059436 (Ku) in patients (p) with advanced tumours","volume":"24","author":"Fong","year":"2006","journal-title":"Journal of Clinical Oncology (Meeting Abstracts)"},{"issue":"15 Suppl","key":"10.1002\/14651858.CD007929.pub3-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"5510","DOI":"10.1200\/jco.2008.26.15_suppl.5510","article-title":"AZD2281 (KU-0059436), a PARP (poly ADP-ribose polymerase) inhibitor with single agent anticancer activity in patients with BRCA deficient ovarian cancer: Results from a phase I study","volume":"26","author":"Fong","year":"2008","journal-title":"Journal of Clinical Oncology (Meeting Abstracts)"},{"issue":"2","key":"10.1002\/14651858.CD007929.pub3-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa0900212","article-title":"Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers","volume":"361","author":"Fong","year":"2009","journal-title":"New England Journal of Medicine"},{"issue":"9","key":"10.1002\/14651858.CD007929.pub3-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/S1470-2045(11)70214-5","article-title":"Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: A phase 2, multicentre, open-label, non-randomised study","volume":"12","author":"Gelmon","year":"2011","journal-title":"Lancet Oncology"},{"issue":"3","key":"10.1002\/14651858.CD007929.pub3-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/nrc2342","article-title":"DNA repair pathways as targets for cancer therapy","volume":"8","author":"Helleday","year":"2008","journal-title":"Nature Reviews Cancer"},{"key":"10.1002\/14651858.CD007929.pub3-BIB0027|cit27","doi-asserted-by":"crossref","unstructured":"Lee J-M Liu J Choyke PL Elbuluk O Turkbey IB Trepel JB Lee M-J Cao L Houston ND Gordon N Figg WD Barry WT Matulonis U Birrer MJ Ivy P Kohn EC Biomarker correlates from the randomized phase 2 trial of the PARP inhibitor olaparib (O) with or without the antiangiogenic TKI cediranib (C) in recurrent platinum-sensitive ovarian cancer (NCT01116648) Journal of clinical oncology 2014 (suppl; abstr 5535)","DOI":"10.1200\/jco.2014.32.15_suppl.5535"},{"issue":"4","key":"10.1002\/14651858.CD007929.pub3-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.coph.2008.06.016","article-title":"Targeted therapy for cancer using PARP inhibitors","volume":"8","author":"Lord","year":"2008","journal-title":"Current Opinion in Pharmacology"},{"key":"10.1002\/14651858.CD007929.pub3-BIB0029|cit29","doi-asserted-by":"crossref","unstructured":"Liu J Barry WT Birrer MJ Lee J-M Buckanovich RJ Fleming GF Rimel B Buss MK Nattam SR Hurteau J Luo W Quy P Obermayer E Whalen C Lee H Winer EP Kohn EC Ivy SP Matulonis U A randomized phase 2 trial comparing efficacy of the combination of the PARP inhibitor olaparib and the antiangiogenic cediranib against olaparib alone in recurrent platinum-sensitive ovarian cancer. Journal of Clinical Oncology, 2014 ASCO Annual Meeting Abstracts 32(15_suppl)","DOI":"10.1200\/jco.2014.32.15_suppl.lba5500"},{"issue":"11","key":"10.1002\/14651858.CD007929.pub3-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1016\/S1470-2045(14)70391-2","article-title":"Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study","volume":"15","author":"Liu","year":"2014","journal-title":"Lancet oncology"},{"key":"10.1002\/14651858.CD007929.pub3-BIB0031|cit31","doi-asserted-by":"crossref","unstructured":"Moore KN Zhang X-Y Agarwal S Patel MR Burris HA Martell RE Kansra V Food effect substudy of a phase 3 randomized double-blind trial of maintenance with niraparib (MK4827), a poly(ADP)ribose polymerase (PARP) inhibitor versus placebo in patients with platinum-sensitive ovarian cancer. Journal of Clinical Oncology, 2014 ASCO Annual Meeting Abstracts. May 2014 e16531","DOI":"10.1200\/jco.2014.32.15_suppl.e16531"},{"issue":"1","key":"10.1002\/14651858.CD007929.pub3-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.ygyno.2008.09.034","article-title":"Platinum compounds 30 years after the introduction of cisplatin: implications for the treatment of ovarian cancer","volume":"112","author":"Muggia","year":"2009","journal-title":"Gynecologic Oncology"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD007929.pub3-BIB0033|cit33","first-page":"iv305","article-title":"Preliminary results of ARIEL2, a phase 2 open-label study to identify ovarian cancer patients likely to respond to rucaparib","volume":"25","author":"McNeish","year":"2014","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD007929.pub3-BIB0034|cit34","first-page":"1197","article-title":"Emerging treatment options for recurrent ovarian cancer: the potential role of olaparib","volume":"6","author":"Shaw","year":"2013","journal-title":"OncoTargets and Therapy"},{"issue":"4","key":"10.1002\/14651858.CD007929.pub3-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.coph.2005.03.006","article-title":"Targeting the DNA repair defect of BRCA tumours","volume":"5","author":"Turner","year":"2005","journal-title":"Current Opinion in Pharmacology"},{"issue":"18 Suppl","key":"10.1002\/14651858.CD007929.pub3-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"3529","DOI":"10.1200\/jco.2007.25.18_suppl.3529","article-title":"First in human phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of KU-0059436 (Ku), a small molecule inhibitor of poly ADP-ribose polymerase (PARP) in cancer patients (p), including BRCA1\/2 mutation carriers","volume":"25","author":"Yap","year":"2007","journal-title":"Journal of Clinical Oncology (Meeting Abstracts)"},{"issue":"3","key":"10.1002\/14651858.CD007929.pub3-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/nrc2583","article-title":"Beyond chemotherapy: targeted therapies in ovarian cancer","volume":"9","author":"Yap","year":"2009","journal-title":"Nature Reviews Cancer"},{"key":"10.1002\/14651858.CD007929.pub3-BIB0038|cit38","unstructured":"DiSilvestro P Moore K A phase III, randomised, double blind, placebo controlled, multicentre study of olaparib maintenance monotherapy in patients with BRCA mutated advanced (FIGO stage III-IV) ovarian cancer following first line platinum based chemotherapy https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01844986 2013"},{"key":"10.1002\/14651858.CD007929.pub3-BIB0039|cit39","doi-asserted-by":"crossref","unstructured":"Moore KN DiSilvestro P Lowe ES Garnett S Pujade-Lauraine E SOLO1 and SOLO2: Randomized phase III trials of olaparib in patients (pts) with ovarian cancer and a BRCA1\/2 mutation (BRCAm). J Clin Oncol (Meeting Abstracts) May 2014 TPS5616","DOI":"10.1200\/jco.2014.32.15_suppl.tps5616"},{"key":"10.1002\/14651858.CD007929.pub3-BIB0040|cit40","doi-asserted-by":"crossref","unstructured":"Matulonis U Mahner S Wenham RM Ledermann JA Monk BJ Del Campo JM Berek JS Vergote I Fabbro M Katsaros D Marth C Lorusso D Herrstedt J Agarwal S RMartell RE Mirza MR A phase 3 randomized double-blind trial of maintenance with niraparib versus placebo in patients with platinum-sensitive ovarian cancer (ENGOT-OV16\/NOVA trial). Journal of Clinical Oncology, 2014 ASCO Annual Meeting Abstracts 32(15_sppl)","DOI":"10.1200\/jco.2014.32.15_suppl.tps5625"},{"key":"10.1002\/14651858.CD007929.pub3-BIB0041|cit41","doi-asserted-by":"crossref","unstructured":"Mirza M Berek JS Vergote I Wenham RM Del Campo JM Oza AM Mahner S Monk BJ Fabbro M Ledermann JA Marth C Bruchim I Katsaros D Lorusso D Malander S Dorum A Agarwal S Martell RE Matulonis U Engot-ov16\/nova: A phase 3 randomized double-blind trial of maintenance with PARP-inhibitor niraparib versus placebo in patients with platinum-sensitive ovarian cancer International journal of gynecological cancer 2014;Conference: 15th Biennial Meeting of the International Gynecologic Cancer Society Melbourne, VIC Australia. Conference Start: 20141108 Conference End: 20141111. Conference Publication 2014 33 34","DOI":"10.1093\/annonc\/mdu338.65"},{"key":"10.1002\/14651858.CD007929.pub3-BIB0042|cit42","unstructured":"Mirza MR Matulonis U A maintenance study with niraparib versus placebo in patients with platinum sensitive ovarian cancer https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01847274 2013"},{"key":"10.1002\/14651858.CD007929.pub3-BIB0043|cit43","doi-asserted-by":"crossref","unstructured":"Moore KN DiSilvestro P Lowe ES Garnett S Pujade-Lauraine E SOLO1 and SOLO2: Randomized phase III trials of olaparib in patients (pts) with ovarian cancer and a BRCA1\/2 mutation (BRCAm). Journal of Clinical Oncology, 2014 ASCO Annual Meeting Abstracts.Vol 32, No 15_suppl (May 20 Supplement), 2014: TPS5616 2014","DOI":"10.1200\/jco.2014.32.15_suppl.tps5616"},{"key":"10.1002\/14651858.CD007929.pub3-BIB0044|cit44","unstructured":"Pujade-Lauraine E Phase III randomised, double blind, placebo controlled study of olaparib maintenance monotherapy in platinum sensitive relapsed BRCA mutated ovarian cancer patients with a complete or partial response following platinum based chemotherapy https:\/\/clinicaltrials.gov\/NCT01874353 2013"},{"key":"10.1002\/14651858.CD007929.pub3-BIB0045|cit45","unstructured":"A study of rucaparib as switch maintenance following platinum-based chemotherapy in patients with platinum-sensitive, high-grade serous or endometrioid epithelial ovarian, primary peritoneal or fallopian tube cancer (ARIEL3) ClinicalTrials.gov website"},{"key":"10.1002\/14651858.CD007929.pub3-BIB0046|cit46","doi-asserted-by":"crossref","unstructured":"Swisher EM McNeish IA ColemanRL Brenton J Kaufmann SH A Allen AR Raponi M Giordano H Maloney L JIsaacson J aLedermann JA ARIEL 2\/3: An integrated clinical trial program to assess activity of rucaparib in ovarian cancer and to identify tumor molecular characteristics predictive of response. J Clin Oncol (Meeting Abstracts) vol. 32 no. 15_suppl TPS5619 May 2014 TPS5619","DOI":"10.1200\/jco.2014.32.15_suppl.tps5619"},{"issue":"7035","key":"10.1002\/14651858.CD007929.pub3-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/nature03443","article-title":"Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase","volume":"434","author":"Bryant","year":"2005","journal-title":"Nature"},{"issue":"6","key":"10.1002\/14651858.CD007929.pub3-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1093\/nar\/gkl108","article-title":"Inhibition of poly (ADP-ribose) polymerase activates ATM which is required for subsequent homologous recombination repair","volume":"34","author":"Bryant","year":"2006","journal-title":"Nucleic Acids Research"},{"key":"10.1002\/14651858.CD007929.pub3-BIB0049|cit49","unstructured":"Cancer Therapy Evaluation Program (CTEP), Common Terminology Criteria for Adverse Events, Version 4.03, DCTD, NCI, NIH, DHHS US Department of Health and Human Services (http:\/\/ctep.cancer.gov)"},{"issue":"4","key":"10.1002\/14651858.CD007929.pub3-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/S146239940500904X","article-title":"PARP inhibitors for cancer therapy","volume":"7","author":"Curtin","year":"2005","journal-title":"Expert Reviews in Molecular Medicine"},{"key":"10.1002\/14651858.CD007929.pub3-BIB0051|cit51","doi-asserted-by":"crossref","DOI":"10.1002\/9780470693926.ch15","article-title":"Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis","volume-title":"Systematic Reviews in Health Care: Meta-Analysis in Context","author":"Deeks","year":"2001"},{"issue":"3","key":"10.1002\/14651858.CD007929.pub3-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Controlled Clinical Trials"},{"key":"10.1002\/14651858.CD007929.pub3-BIB0053|cit53","unstructured":"Committee for Medicinal Products for Human Use (CHMP). European Medicines Agency Summary of opinion (initial authorisation): Lynparza (olaparib) European Medicines Agency, London"},{"key":"10.1002\/14651858.CD007929.pub3-BIB0054|cit54","unstructured":"Adept Scientific Ltd. Endnote X6 2012"},{"issue":"5","key":"10.1002\/14651858.CD007929.pub3-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.ajog.2013.04.019","article-title":"The role of the fallopian tube in the origin of ovarian cancer","volume":"209","author":"Erickson","year":"Nov 2013","journal-title":"American Journal of Obstetrics and Gynecology"},{"issue":"7035","key":"10.1002\/14651858.CD007929.pub3-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/nature03445","article-title":"Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy","volume":"434","author":"Farmer","year":"2005","journal-title":"Nature"},{"key":"10.1002\/14651858.CD007929.pub3-BIB0057|cit57","unstructured":"Ferlay J Soerjomataram I Ervik M Dikshit R Eser S Mathers C GLOBOCAN 2012v1.0, Cancer Incidence and Mortality Worldwide IARC CancerBase 2013"},{"key":"10.1002\/14651858.CD007929.pub3-BIB0058|cit58","unstructured":"McMaster University GRADEpro[Computer program on www.gradepro.org]. 2014"},{"issue":"22","key":"10.1002\/14651858.CD007929.pub3-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"3570","DOI":"10.1200\/JCO.2009.27.2997","article-title":"Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer","volume":"28","author":"Hennessy","year":"2010","journal-title":"Journal of Clinical Oncology"},{"issue":"7414","key":"10.1002\/14651858.CD007929.pub3-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD007929.pub3-BIB0061|cit61","unstructured":"Higgins JPT Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"issue":"5","key":"10.1002\/14651858.CD007929.pub3-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/nrd1718","article-title":"Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors","volume":"4","author":"Jagtap","year":"2005","journal-title":"National Reviews of Drug Discovery"},{"issue":"2","key":"10.1002\/14651858.CD007929.pub3-BIB0063|cit63","first-page":"71","article-title":"Cancer statistics","volume":"58","author":"Jemal","year":"2008","journal-title":"CA: A Cancer Journal for Clinicians"},{"issue":"8","key":"10.1002\/14651858.CD007929.pub3-BIB0064|cit64","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005343","article-title":"Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer","author":"Morrison","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD007929.pub3-BIB0065|cit65","volume-title":"Familial breast cancer: Classification and care of people at risk of familial breast cancer and management of breast cancer and related risks in people with a family history of breast cancer - guidance (CG164)","author":"National Institute for Clinical Excellence","year":"2013"},{"issue":"24","key":"10.1002\/14651858.CD007929.pub3-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1002\/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8","article-title":"Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints","volume":"17","author":"Parmar","year":"1998","journal-title":"Statistics in Medicine"},{"issue":"6","key":"10.1002\/14651858.CD007929.pub3-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1007\/s12094-008-0207-8","article-title":"Poly(ADP-ribose)polymerase-1 (PARP-1) in carcinogenesis: potential role of PARP inhibitors in cancer treatment","volume":"10","author":"Peralta-Leal","year":"2008","journal-title":"Clinical Translations in Oncology"},{"key":"10.1002\/14651858.CD007929.pub3-BIB0068|cit68","volume-title":"Cancer Trends in England and Wales","author":"Quinn","year":"2001"},{"issue":"5","key":"10.1002\/14651858.CD007929.pub3-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1158\/1078-0432.CCR-06-2260","article-title":"Current development of clinical inhibitors of poly(ADP-ribose) polymerase in oncology","volume":"13","author":"Ratnam","year":"2007","journal-title":"Clinical Cancer Research"},{"issue":"237","key":"10.1002\/14651858.CD007929.pub3-BIB0070|cit70","first-page":"1","article-title":"The role of PARP inhibitors in the treatment of gynecologic malignancies","volume":"3","author":"Reinbolt","year":"2013","journal-title":"Frontiers in Oncology"},{"key":"10.1002\/14651858.CD007929.pub3-BIB0071|cit71","unstructured":"The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) 2014"},{"issue":"3","key":"10.1002\/14651858.CD007929.pub3-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1086\/318787","article-title":"Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer","volume":"68","author":"Risch","year":"2001","journal-title":"American Journal of Human Genetics"},{"issue":"8","key":"10.1002\/14651858.CD007929.pub3-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1111\/j.1471-0528.1989.tb03341.x","article-title":"Revised FIGO staging for gynaecological cancer","volume":"96","author":"Shepherd","year":"1989","journal-title":"British Journal of Obstetrics and Gynaecology"},{"issue":"1","key":"10.1002\/14651858.CD007929.pub3-BIB0074|cit74","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001418","article-title":"Chemotherapy for advanced ovarian cancer","author":"Stewart","year":"1999","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD007929.pub3-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1038\/nrc1457","article-title":"Hallmarks of 'BRCAness' in sporadic cancers","volume":"4","author":"Turner","year":"2004","journal-title":"Nature Reviews Cancer"},{"key":"10.1002\/14651858.CD007929.pub3-BIB0076|cit76","unstructured":"Vergote I Trop\u00e9 CG Amant F Kristensen GB Sardi JE Ehlen T EORTC-GCG\/NCIC-CTG Randomised trial comparing primary debulking surgery with neoadjuvant chemotherapy in stage IIIC-IV ovarian, fallopian tube and peritoneal cancer (OVCA) Proceedings of the 12th Biennial Meeting of the International Gynecologic Cancer Society - IGCS Bangkok 2008"},{"key":"10.1002\/14651858.CD007929.pub3-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1158\/1535-7163.MCT-11-0004","article-title":"Sorafenib enhances the anti-tumor effects of chemo-radiation treatment by down-regulating DNA repair proteins","volume":"10","author":"Yadav","year":"2011","journal-title":"Molecular Cancer Therapeutics"},{"issue":"5","key":"10.1002\/14651858.CD007929.pub3-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"515","DOI":"10.2174\/187152007781668715","article-title":"PARP inhibitor development for systemic cancer targeting","volume":"7","author":"Zaremba","year":"2007","journal-title":"Anti-cancer Agents in Medicinal Chemistry"},{"issue":"4","key":"10.1002\/14651858.CD007929.pub3-BIB0079|cit79","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007929","article-title":"DNA-repair pathway inhibitors for the treatment of ovarian cancer","author":"Martinek","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"6","key":"10.1002\/14651858.CD007929.pub3-BIB0080|cit80","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007929.pub2","article-title":"DNA-repair pathway inhibitors for the treatment of ovarian cancer","author":"Martinek","year":"2010","journal-title":"Cochrane Database of Systematic Reviews"}],"updated-by":[{"DOI":"10.1002\/14651858.cd007929.pub4","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2022,2,16]],"date-time":"2022-02-16T00:00:00Z","timestamp":1644969600000}}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD007929.pub3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T22:15:20Z","timestamp":1628547320000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD007929.pub3"}},"subtitle":[],"editor":[{"name":"Cochrane Gynaecological, Neuro-oncology and Orphan Cancer Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2015,5,20]]},"references-count":80,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd007929.pub3","relation":{"new_version":[{"id-type":"doi","id":"10.1002\/14651858.CD007929.pub4","asserted-by":"object"}]},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,5,20]]}}}